Chinese COVID-19 Vaccine Shows 50.4 Percent Efficacy in Brazil Trial

Chinese COVID-19 Vaccine Shows 50.4 Percent Efficacy in Brazil Trial
A technician works in a lab at Sinovac Biotech, where the company is producing its potential COVID-19 vaccine CoronaVac, during a media tour in Beijing on Sept. 24, 2020. Kevin Frayer/Getty Images
Eva Fu
Updated:

A leading Chinese COVID-19 vaccine candidate has been found to be 50.4 percent effective, according to the results of a late-stage trial in Brazil, a potential setback to the Chinese regime as it seeks to leverage the vaccine to boost its global image.

The results from Brazil’s state-funded Butantan Institute on Jan. 12 were just enough to pass the 50 percent threshold set by the World Health Organization for regulatory approval. It was far lower than initial claims announced last week that touted a 78 percent efficacy rate.

Eva Fu
Eva Fu
Reporter
Eva Fu is an award-winning, New York-based journalist for The Epoch Times focusing on U.S. politics, U.S.-China relations, religious freedom, and human rights. Contact Eva at [email protected]
twitter
Related Topics